Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 29Stomach Neoplasms 13Esophageal Neoplasms 13Colorectal Neoplasms 12Esophageal Squamous Cell Carcinoma 10Rectal Neoplasms 7Pancreatic Neoplasms 7Biliary Tract Neoplasms 7Head and Neck Neoplasms 5Colonic Neoplasms 5Cholangiocarcinoma 5Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 4Locally Advanced Rectal Cancer 4Liver Neoplasms 4Ovarian Neoplasms 3Neoplasms 3Melanoma 3Carcinoma, Renal Cell 3Anus Neoplasms 3Turcot syndrome 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pathologic Complete Response 2Gastric / Gastroesophageal Junction Adenocarcinoma 2Digestive System Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1

Interventions

Fluorouracil 67Radiotherapy 53Cisplatin 52Oxaliplatin 47Leucovorin 37Paclitaxel 36Irinotecan 27Docetaxel 23Capecitabine 20Nivolumab 17Carboplatin 16pembrolizumab 15Radiation 15Neoadjuvant Therapy 15Surgical Procedures, Operative 12Cetuximab 12durvalumab 9Drug Therapy 9Biopsy 9Taxes 8Folfox protocol 8Chemotherapy, Adjuvant 8Trastuzumab 7Magnetic Resonance Spectroscopy 7Gefitinib 7Endoscopy 7tremelimumab 6Specimen Handling 6Endoscopy, Digestive System 6Ramucirumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Immune Checkpoint Inhibitors × Gastrointestinal × Clear all
NCT05001360 2021-10-27

Study of FMT Combined With Nivolumab in Gastric Cancer

Fujian Cancer Hospital

Phase NA Withdrawn
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡